Literature DB >> 16714251

Vitamin D and its binding protein Gc: long-term variability in peri- and postmenopausal women with and without hormone replacement therapy.

L Rejnmark1, A L Lauridsen, C Brot, P Vestergaard, L Heickendorff, E Nexo, L Mosekilde.   

Abstract

OBJECTIVE: Measurement of plasma 25-hydroxyvitamin D (25OHD) level is often used to evaluate a patient's vitamin D status. The purpose of this study was to investigate the variability in individual plasma 25OHD- and vitamin D-binding protein- (Gc) levels over a 5-year period in postmenopausal women with and without hormone replacement therapy (HRT).
MATERIAL AND METHODS: A total of 187 women were followed-up for 5 years. At baseline, 89 women were allocated to treatment with HRT, given orally. Measurements were performed at baseline and after 1, 2 and 5 years of follow-up.
RESULTS: At baseline, 25OHD levels were positively associated with sunbathing and use of vitamin D supplements, and inversely associated with smoking. HRT therapy increased plasma levels of Gc (+8 %) but did not affect 25OHD levels or the free 25OHD index (molar ratio of 25OHD- to Gc levels). Among those classified in the lowest 25OHD tertile at baseline, 40 % remained in the lowest tertile during all subsequent measurement time-points. Similarly, 32 % of those classified in the highest baseline tertile remained in the highest tertile during all subsequent measurements. Use of the free 25OHD index showed similar results. No independent predictors of changes in vitamin D tertiles during follow-up were identified, which suggests that the observed variation was caused by the intra-individual variation in measured parameters. For all participants, the within-patient variability in 25OHD measurements was between 13 % and 19 %.
CONCLUSIONS: In healthy postmenopausal women, HRT increases Gc levels. Owing to the high intra-individual variation in plasma 25OHD, it seems questionable to use a single estimate as a predictor of individual vitamin D status.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16714251     DOI: 10.1080/00365510600570623

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  21 in total

1.  Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Authors:  Jonathan N Hofmann; Kai Yu; Ronald L Horst; Richard B Hayes; Mark P Purdue
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-23       Impact factor: 4.254

2.  Dietary, lifestyle, and genetic determinants of vitamin D status: a cross-sectional analysis from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Germany study.

Authors:  Tilman Kühn; Rudolf Kaaks; Birgit Teucher; Frank Hirche; Jutta Dierkes; Cornelia Weikert; Verena Katzke; Heiner Boeing; Gabriele I Stangl; Brian Buijsse
Journal:  Eur J Nutr       Date:  2013-09-05       Impact factor: 5.614

3.  Changes in vitamin D supplement use and baseline plasma 25-hydroxyvitamin D concentration predict 5-y change in concentration in postmenopausal women.

Authors:  Melissa A Kluczynski; Jean Wactawski-Wende; Mary E Platek; Carol A DeNysschen; Kathleen M Hovey; Amy E Millen
Journal:  J Nutr       Date:  2012-07-25       Impact factor: 4.798

4.  Racial differences in the association of serum 25-hydroxyvitamin D concentration with coronary heart disease events.

Authors:  Cassianne Robinson-Cohen; Andrew N Hoofnagle; Joachim H Ix; Michael C Sachs; Russell P Tracy; David S Siscovick; Bryan R Kestenbaum; Ian H de Boer
Journal:  JAMA       Date:  2013-07-10       Impact factor: 56.272

5.  Reproducibility of serum 25-hydroxyvitamin d and vitamin D-binding protein levels over time in a prospective cohort study of black and white adults.

Authors:  Jennifer S Sonderman; Heather M Munro; William J Blot; Lisa B Signorello
Journal:  Am J Epidemiol       Date:  2012-09-13       Impact factor: 4.897

6.  VITAMIN D-BINDING PROTEIN IN HEALTHY PRE- AND POSTMENOPAUSAL WOMEN: RELATIONSHIP WITH ESTRADIOL CONCENTRATIONS.

Authors:  L Claudia Pop; Sue A Shapses; Brian Chang; Wei Sun; Xiangbing Wang
Journal:  Endocr Pract       Date:  2015-06-29       Impact factor: 3.443

7.  Associations of Circulating 25-Hydroxyvitamin D3 Concentrations With Incident, Sporadic Colorectal Adenoma Risk According to Common Vitamin D-Binding Protein Isoforms.

Authors:  David C Gibbs; Veronika Fedirko; Caroline Um; Myron D Gross; Bharat Thyagarajan; Roberd M Bostick
Journal:  Am J Epidemiol       Date:  2018-09-01       Impact factor: 4.897

8.  Mineral metabolism markers and the long-term risk of hip fracture: the cardiovascular health study.

Authors:  Cassianne Robinson-Cohen; Ronit Katz; Andrew N Hoofnagle; Jane A Cauley; Curt D Furberg; John A Robbins; Zhao Chen; David S Siscovick; Ian H de Boer; Bryan Kestenbaum
Journal:  J Clin Endocrinol Metab       Date:  2011-04-20       Impact factor: 5.958

9.  25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification.

Authors:  Ian H de Boer; Bryan Kestenbaum; Abigail B Shoben; Erin D Michos; Mark J Sarnak; David S Siscovick
Journal:  J Am Soc Nephrol       Date:  2009-05-14       Impact factor: 10.121

10.  A prospective investigation of serum 25-hydroxyvitamin D and risk of lymphoid cancers.

Authors:  Unhee Lim; D Michal Freedman; Bruce W Hollis; Ronald L Horst; Mark P Purdue; Nilanjan Chatterjee; Stephanie J Weinstein; Lindsay M Morton; Arthur Schatzkin; Jarmo Virtamo; Martha S Linet; Patricia Hartge; Demetrius Albanes
Journal:  Int J Cancer       Date:  2009-02-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.